ijms-logo

Journal Browser

Journal Browser

Microbial Infections and Novel Biological Molecules for Treatment: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 411

Editor


E-Mail Website
Guest Editor
School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast 4222, Australia
Interests: molecular biology; infectious diseases; biochemistry; natural product discovery; antimicrobial resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It has been 35 years since the introduction of a new class of antibiotics. As such, new antibiotic agents are urgently needed, particularly in the fight against antimicrobial resistance (AMR). Whilst AMR was first observed in bacterial species, it has also arisen in mycobacterial, viral, fungal, protozoal species and other types of species.

There have been candidates for novel antimicrobial drugs across a variety of structurally dissimilar compounds, showing promise as agents that may successfully treat microbial infections. However, this search continues as the rates of resistant infections increase. Ongoing studies are required to identify and fully characterize novel anti-infective drugs that are suitable for AMR infections so they can be treated successfully and the exacerbation of AMR can be prevented.

This special issue is a continuation of Volume I: “Microbial Infections and Novel Biological Molecules for Treatment.

Dr. Matthew Cheesman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbial infections
  • infectious diseases
  • new antibiotics
  • antimicrobial resistance (AMR)
  • antimicrobial drugs
  • active substance
  • bacterial
  • virus

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 5799 KB  
Article
Synergy Between the Auranofin Analogue PEt3AuCl and Membrane Disruptors, Efflux-Pump Blockers, and Glutathione-Depletors Uncovers Tolerance Pathways in Pseudomonas aeruginosa
by Beatrice Amato, Diletta Mazzantini, José Aleixo de Azevedo-França, Giuseppantonio Maisetta, Emilia Ghelardi, Semih Esin, Luigi Messori and Giovanna Batoni
Int. J. Mol. Sci. 2026, 27(10), 4610; https://doi.org/10.3390/ijms27104610 - 21 May 2026
Viewed by 294
Abstract
Auranofin (AF), an FDA-approved drug for rheumatoid arthritis, exhibits strong antibacterial activity against Gram-positive bacteria, while Gram-negative species remain largely tolerant. This study assessed the antimicrobial activity of AF and three analogues against clinically relevant Gram-negative pathogens and explored tolerance mechanisms in Pseudomonas [...] Read more.
Auranofin (AF), an FDA-approved drug for rheumatoid arthritis, exhibits strong antibacterial activity against Gram-positive bacteria, while Gram-negative species remain largely tolerant. This study assessed the antimicrobial activity of AF and three analogues against clinically relevant Gram-negative pathogens and explored tolerance mechanisms in Pseudomonas aeruginosa. Broth microdilution assays were performed on reference strains and clinical isolates of Escherichia coli, Klebsiella pneumoniae, and P. aeruginosa. Synergy studies with the most active analogue, PEt3AuCl (AF-Cl), were conducted against P. aeruginosa using polymyxin B (PMB), two efflux-pump inhibitors, and two glutathione (GSH) depletors. Gold compounds showed MICs between 4 and >64 µg/mL, with AF-Cl displaying the highest activity. AF-Cl activity was markedly enhanced by PMB and efflux-pump inhibitors, indicating that outer membrane permeability and efflux contribute to tolerance. Additionally, GSH depletion significantly potentiated AF-Cl, implicating redox homeostasis in resistance. Overall, AF-Cl shows potential against Gram-negative bacteria when combined with agents targeting membrane integrity, efflux systems, or redox balance, supporting combinatorial strategies to overcome resistance in P. aeruginosa and related pathogens. Full article
Show Figures

Figure 1

Back to TopTop